Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Twenty-four hours after plating 1×105 Shh-EGFP cells, media was changed to serum-free media containing vehicle, 8µM Nutlin-3a, and/or Shh (3µg/mL). Cells were also transduced with lentivirus containing pLKO.1 empty vector or LentiORF-YFP-WIP1. 48 hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-WIP1 or α-Ki-67 antibody, and mounted using media containing DAPI. Scale bar, 100µm.

    Oncogene, 2016, 35(42):5552-5564. Nutlin-3a purchased from Selleck.

    Assessment of cell viability with WST1 tetrazolium salt assays in TP53 WT and KO isogenic cell lines after exposure to Nutlin-3a.

    Br J Haematol, 2017, 177(1):80-94. Nutlin-3a purchased from Selleck.

  • Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment.

    J Cell Mol Med, 2017, 21(12):3435-3444. Nutlin-3a purchased from Selleck.

    Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;rcGxKSzVyPUCuOlEzOzdizszN M4PWO3NCVkeHUh?=
H4 M4[xNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PZOWlEPTB;MD62OlI5KM7:TR?= NHjieVNUSU6JRWK=
PA-1 Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDSdYh7UUN3ME2wMlg4ODl4IN88US=> MWTTRW5ITVJ?
NKM-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXFTWM2OD1zLkC0PVMyKM7:TR?= NGrWUpdUSU6JRWK=
NEC8 MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFwMkG1O|Ih|ryP NXnLS25lW0GQR1XS
EoL-1-cell MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHDTWM2OD1zLkK2O|AyKM7:TR?= M{LXcHNCVkeHUh?=
K5 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\C[4xTUUN3ME2xMlQzODd{IN88US=> MmKwV2FPT0WU
QIMR-WIL Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\MTWM2OD1zLk[wPFU1KM7:TR?= M13qd3NCVkeHUh?=
MOLT-16 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTtTWM2OD1zLke4OlA1KM7:TR?= MonaV2FPT0WU
CHP-212 NF7sNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;PTWM2OD1zLkixN|Y6KM7:TR?= NGnqPWpUSU6JRWK=
CTB-1 NIrlVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJwMEKyOFYh|ryP MWTTRW5ITVJ?
MOLT-4 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7ZT5U3UUN3ME2yMlMzQDV|IN88US=> NEnGbZRUSU6JRWK=
A101D NGPoeZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH5NGVTUUN3ME2yMlM2ODFizszN Mk\6V2FPT0WU
DOHH-2 MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;YfmlEPTB;Mj60NlI4QSEQvF2= NGPt[JhUSU6JRWK=
ES4 NYXGbFc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TjU2lEPTB;Mj60N|E2PSEQvF2= MX3TRW5ITVJ?
SW780 M2DYOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJwNUC4PFMh|ryP MV3TRW5ITVJ?
VA-ES-BJ MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJwNUSxNUDPxE1? M1\CZ3NCVkeHUh?=
RPMI-8866 NYrnclh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jJUGlEPTB;Mj61OlIyPCEQvF2= NVW4PVJ3W0GQR1XS
ML-2 Mk\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPDTWM2OD1{LkW2OVc3KM7:TR?= NULFNFlwW0GQR1XS
MSTO-211H M2jlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7Gb5ZKSzVyPUKuOVc1PTFizszN M{PvR3NCVkeHUh?=
JVM-3 M37DTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL4TWM2OD1{LkW5N|I1KM7:TR?= MUjTRW5ITVJ?
A3-KAW MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvIcmYyUUN3ME2yMlYyQDF6IN88US=> MYXTRW5ITVJ?
DK-MG NGW3c3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUf4XHNpUUN3ME2yMlYzPDdzIN88US=> MkXBV2FPT0WU
LNCaP-Clone-FGC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJwNkSzNVgh|ryP M3PxfnNCVkeHUh?=
HT-144 Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rld2lEPTB;Mj62OFU4PyEQvF2= MkPqV2FPT0WU
NB69 Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJwNkWzN|Qh|ryP NFXaSIZUSU6JRWK=
A172 M{m2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr4NFBKSzVyPUKuOlc2QDhizszN NYjmZ5Y{W0GQR1XS
RS4-11 NVq1OVVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XxT2lEPTB;Mj63NlQxPyEQvF2= NELKbIpUSU6JRWK=
DU-4475 M2LINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HXVWlEPTB;Mj63PVUxOiEQvF2= MVXTRW5ITVJ?
SJSA-1 NI\SWZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJwOEK1OVYh|ryP NFXWTIxUSU6JRWK=
BV-173 Ml\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rISGlEPTB;Mj64OFQ{QSEQvF2= M1\VenNCVkeHUh?=
U-2-OS NVPXdo5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmH1TWM2OD1{LkmxNFch|ryP NWXCVmJnW0GQR1XS
CHP-134 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HiW2lEPTB;Mj65N|g5OiEQvF2= MUjTRW5ITVJ?
D-502MG M1vGd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJwOUexOVQh|ryP M2fBc3NCVkeHUh?=
KS-1 MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mme4TWM2OD1|LkCxOlI{KM7:TR?= NFG2O4FUSU6JRWK=
A204 NH\tfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTNwMEW1PFgh|ryP MnHJV2FPT0WU
KGN NF23THRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkf3TWM2OD1|LkC4OFk3KM7:TR?= MoLzV2FPT0WU
NCI-H292 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHywWVVKSzVyPUOuNVIxOjhizszN MVXTRW5ITVJ?
CAKI-1 M3PZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTNwMUK2PVQh|ryP NWLYR2R7W0GQR1XS
C2BBe1 M{f5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTNwMUewNlYh|ryP M4rnbnNCVkeHUh?=
NB10 NX;kSIpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnXU5lLUUN3ME2zMlIxQTZ4IN88US=> M2jU[3NCVkeHUh?=
MHH-NB-11 M3nHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHjTWM2OD1|LkK2PFI4KM7:TR?= MojGV2FPT0WU
NCI-SNU-1 MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTNwMke4OFMh|ryP NWHLfmt5W0GQR1XS
HCT-116 NVjKcnZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXKN3RKSzVyPUOuN|A{OzVizszN M3v2NXNCVkeHUh?=
G-401 MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPWV|JKSzVyPUOuN|Y{OjJizszN MmrUV2FPT0WU
MN-60 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHmOmRKSzVyPUOuOFQxQTJizszN NFO4fXBUSU6JRWK=
SW982 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor1TWM2OD1|LkWwPFQ5KM7:TR?= NFPTPXhUSU6JRWK=
RKO NVLuPIx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HpdmlEPTB;Mz61N|k{PiEQvF2= MXfTRW5ITVJ?
D-283MED MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7OTWhnUUN3ME2zMlU4QTh4IN88US=> MYfTRW5ITVJ?
LB996-RCC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDoe3FKSzVyPUOuOlI2PThizszN NVHsOJpxW0GQR1XS
A549 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[xZ5dKSzVyPUOuOlM2PTJizszN NX7YbWNwW0GQR1XS
LB2241-RCC M36x[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPyTWM2OD1|Lk[1O|A5KM7:TR?= NULMeZZXW0GQR1XS
SK-HEP-1 Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HaTGlEPTB;Mz63OFI6PyEQvF2= NUX4bY9qW0GQR1XS
G-402 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK5XYVKSzVyPUOuPFA5OzJizszN NXzrPVd2W0GQR1XS
GOTO NIjLWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\jSJQ4UUN3ME2zMlg1OzN|IN88US=> MWLTRW5ITVJ?
LOXIMVI MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTNwOEW2O|Uh|ryP NUTnflNNW0GQR1XS
NH-12 NInwO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnu[FlLUUN3ME20MlAyQTV7IN88US=> NXHBfGF[W0GQR1XS
CTV-1 NITkR|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jDeWlEPTB;ND6wO|k4OyEQvF2= MV;TRW5ITVJ?
CP50-MEL-B NH7IVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTXVG02UUN3ME20MlI1Ozl{IN88US=> NXH5NlJQW0GQR1XS
RH-18 M3rITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfBNGxnUUN3ME20MlI4PzB4IN88US=> M4nZV3NCVkeHUh?=
NB17 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPNTWM2OD12LkOxO|Y5KM7:TR?= M17ybHNCVkeHUh?=
A375 M2nVXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln4TWM2OD12LkOzOVI1KM7:TR?= NHXXNXdUSU6JRWK=
IST-MES1 M3\iWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrLfodyUUN3ME20MlQyPDFzIN88US=> MYLTRW5ITVJ?
MZ2-MEL M2\XVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvRTWM2OD12LkWwNVU2KM7:TR?= MofSV2FPT0WU
CAL-54 NU\BWYw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ntNmlEPTB;ND61N|AyQSEQvF2= NX[zdmMzW0GQR1XS
NCI-H28 M4fie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV70SYtuUUN3ME20MlYzPzF5IN88US=> MYXTRW5ITVJ?
D-247MG NInq[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPrNmlTUUN3ME20Mlc2ODd{IN88US=> NIrlW21USU6JRWK=
NCI-H460 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTRwOUGxNlch|ryP M17lfnNCVkeHUh?=
MCF7 NInHcVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVThRVlMUUN3ME21MlQ1OjR2IN88US=> MV7TRW5ITVJ?
697 NYHlRW11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TldGlEPTB;NT60OFU2KM7:TR?= Mn\vV2FPT0WU
ONS-76 NYH4V4ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnyNplKSzVyPUWuOVcxODlizszN NYjLcoFWW0GQR1XS
C32 MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mli0TWM2OD13Lk[wNFI6KM7:TR?= NFfuUYlUSU6JRWK=
OS-RC-2 M2fSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTVwN{O4PFch|ryP NFzjfIxUSU6JRWK=
MEL-HO NIXCXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHNS2NKSzVyPUWuPFU3PjdizszN M4XjWXNCVkeHUh?=
LoVo NYnrbItZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX5WZpKSzVyPU[uNFE3OjRizszN MnrsV2FPT0WU
AGS NXjDd2V5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[5WWlEPTB;Nj6xOFgzQCEQvF2= M{HtfXNCVkeHUh?=
GI-ME-N MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoT2TWM2OD14LkKyOFIyKM7:TR?= MW\TRW5ITVJ?
H-EMC-SS NYPCW2lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnPVINPUUN3ME22MlM5PiEQvF2= NUL5NGk{W0GQR1XS
RVH-421 NYXpRnE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVuzcYtzUUN3ME22MlQzPDJ6IN88US=> NYnIXYZsW0GQR1XS
SW954 M1u1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLFTWM2OD14LkW1OVczKM7:TR?= M{n4bHNCVkeHUh?=
NB5 MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPOZlBKSzVyPU[uOVYyQDNizszN NVO1[YN2W0GQR1XS
NCI-H2122 MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTZwNUi3PVMh|ryP MV\TRW5ITVJ?
AM-38 M2rDRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrEc4hKSzVyPU[uO|U3OzlizszN M{WxSXNCVkeHUh?=
KNS-81-FD M4C5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vqW2lEPTB;Nj63OlQ6PCEQvF2= MX3TRW5ITVJ?
LS-513 M3vWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nOd2lEPTB;Nj63PVAzPiEQvF2= MYrTRW5ITVJ?
A427 NVTF[2VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTZwOEe4Nlkh|ryP NWfiNJRDW0GQR1XS
WM-115 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn5SFlKSzVyPU[uPVMzOyEQvF2= NHvmelhUSU6JRWK=
COLO-829 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjpZXNFUUN3ME23MlI1OTh6IN88US=> NGixS4VUSU6JRWK=
NCI-H1650 M4PRR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvscmpFUUN3ME23MlM6OjJ6IN88US=> NFvIXGJUSU6JRWK=
NCI-H358 NHn6SHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLQXZRKSzVyPUeuOFQ5PzlizszN Mn3PV2FPT0WU
HT-1080 MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDiTWM2OD15LkS4NlU1KM7:TR?= MlXEV2FPT0WU
HCC2218 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnwOWNKSzVyPUeuOlI6PyEQvF2= M1G2e3NCVkeHUh?=
NCI-H661 M{D3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;tdmlEPTB;Nz64O|A3QSEQvF2= MV;TRW5ITVJ?
KM-H2 Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTdwOEi2PVQh|ryP NF;BNGJUSU6JRWK=
RPMI-2650 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vvT2lEPTB;Nz65OFQyPCEQvF2= M3fI[XNCVkeHUh?=
NCI-H226 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITZXpZKSzVyPUiuNlEyOjJizszN MmSwV2FPT0WU
MKN45 M3nSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HoemlEPTB;OD6yOlYxOiEQvF2= MnXUV2FPT0WU
D-392MG MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z0XmlEPTB;OD61NlczOiEQvF2= MmjmV2FPT0WU
RCC10RGB NV3OflU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLDTWM2OD16Lki2Olk2KM7:TR?= NE\nToxUSU6JRWK=
CAL-51 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLoVo1KSzVyPUmuNVAzPTFizszN MVfTRW5ITVJ?
COLO-678 M4TzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHW[mJlUUN3ME25MlMzQDFzIN88US=> M4juTHNCVkeHUh?=
SK-MEL-24 NXnOcZhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7UZmhKSzVyPUmuOVU5PTZizszN Mnz5V2FPT0WU
SK-MEL-30 M4fqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT1TWM2OD17Lkm0OFc3KM7:TR?= M3fK[XNCVkeHUh?=
MMAC-SF MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLjTWM2OD1zMD6zPVYyKM7:TR?= Mlz2V2FPT0WU
NTERA-S-cl-D1 M2PTdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFyLk[1NFgh|ryP NGr0NY9USU6JRWK=
NB12 NV34bZFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\pV2lEPTB;MUGuOVA{KM7:TR?= NILzTYlUSU6JRWK=
UACC-257 MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFG3U4hKSzVyPUGxMlg3QTVizszN MXjTRW5ITVJ?
LAN-6 NV3GcldiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTFzLkm5Nlgh|ryP NX\CN5lwW0GQR1XS
SW1573 M13NXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjwXHNKSzVyPUGyMlMxQDZizszN NXvoc|dDW0GQR1XS
NMC-G1 M2jqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn[5TWM2OD1zMj60NVc2KM7:TR?= NWHnWGR3W0GQR1XS
SHP-77 NWnhSXlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\JbWo6UUN3ME2xNk42PTd2IN88US=> M120V3NCVkeHUh?=
IGROV-1 MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonBTWM2OD1zMj62OVc{KM7:TR?= MX3TRW5ITVJ?
22RV1 MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHibGRWUUN3ME2xNk45ODV7IN88US=> NFPLbItUSU6JRWK=
SK-MEL-3 NW\PZpk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PMU2lEPTB;MUOuN|k4OyEQvF2= M3jjfHNCVkeHUh?=
NCI-H1563 NYHjcmJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzTcVdKUUN3ME2xN{41OjB{IN88US=> NXLHfGViW0GQR1XS
IGR-1 NH;RRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTF2LkCzOFch|ryP NH6yTVFUSU6JRWK=
EW-3 M2ja[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLRTWM2OD1zND6xOlM6KM7:TR?= MVHTRW5ITVJ?
JEG-3 MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTF2LkS5OVMh|ryP NYDSXmM2W0GQR1XS
ES3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILsTI5KSzVyPUG0MlY2PjJizszN NF:4SYdUSU6JRWK=
MDA-MB-175-VII NIrUdllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTF2LkexNVEh|ryP MlHpV2FPT0WU
P30-OHK M1XPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjzdppWUUN3ME2xOU4xPDl4IN88US=> MknCV2FPT0WU
GP5d MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVO0[|c{UUN3ME2xOU4yPDZ4IN88US=> NGnrZVlUSU6JRWK=
HMV-II MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXOTWM2OD1zNT6zN|M{KM7:TR?= MVjTRW5ITVJ?
COLO-679 NFjZfI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHjRo9KSzVyPUG1MlUxOSEQvF2= NYnvdowzW0GQR1XS
JAR MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTzZ444UUN3ME2xOU44OjB3IN88US=> Ml\IV2FPT0WU
NCI-H1666 NWjKZohxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPkeo1OUUN3ME2xOU46Ozl7IN88US=> MYTTRW5ITVJ?
SW48 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTF3Lkm1NVYh|ryP MnPrV2FPT0WU
NCI-H720 NVfldlBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXLelRbUUN3ME2xOU46QTh7IN88US=> NXTRdIVZW0GQR1XS
HT-1197 MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLZTJpsUUN3ME2xOk4xOzV{IN88US=> MlHNV2FPT0WU
HL-60 MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\PTWM2OD1zNj6wN|g1KM7:TR?= NILkPZZUSU6JRWK=
BEN MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmi3TWM2OD1zNj61OlM5KM7:TR?= NXT5XFUyW0GQR1XS
HAL-01 NInuRlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;mOVI1UUN3ME2xOk45QTB7IN88US=> NXHneJpyW0GQR1XS
SW900 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTF4LkmxN|Ih|ryP MlPFV2FPT0WU
SBC-1 MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnqOGNKSzVyPUG3MlU1OjlizszN NWHTSJJVW0GQR1XS
SH-4 M3ezbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvxNXpKSzVyPUG3MlU5PDFizszN NWfIboo{W0GQR1XS
UACC-62 MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH3[YlyUUN3ME2xO{44PjN5IN88US=> M3HhdHNCVkeHUh?=
BHT-101 NGXM[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF7Lki3NFUh|ryP M3\PPHNCVkeHUh?=
DB M3X0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDKTWM2OD1{MT61OlQ6KM7:TR?= MX\TRW5ITVJ?
SK-MEL-1 NHrtZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjYTWM2OD1{MT61PFczKM7:TR?= MmrrV2FPT0WU
NCI-H747 M4e3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH5eo9nUUN3ME2yNk44Ozd7IN88US=> MlfqV2FPT0WU
SK-LU-1 NHHjO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fyPWlEPTB;MkOuN|UzPCEQvF2= NWPoRXl3W0GQR1XS
KG-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfhb5FKSzVyPUKzMlQ6PDZizszN NFj6[2tUSU6JRWK=
LXF-289 M4nHfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr5cld4UUN3ME2yN{44OTRizszN Ml;aV2FPT0WU
HCC1954 M4O3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJ2Lki4OFQh|ryP NXnBZmhrW0GQR1XS
Ramos-2G6-4C10 M1LndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJ4LkS5PFEh|ryP Ml31V2FPT0WU
DBTRG-05MG M4fvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnP1TWM2OD1{Nj62OFg5KM7:TR?= M3;ZNHNCVkeHUh?=
NCI-H2052 Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfVN2tKSzVyPUK3MlU3QDRizszN MVHTRW5ITVJ?
RMG-I MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e2OGlEPTB;MkmuOFE{QSEQvF2= NYnJfYwxW0GQR1XS
H9 NGDQRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTJTWM2OD1|MT6zNFA5KM7:TR?= NIXmRphUSU6JRWK=
GR-ST M1fRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTN{LkS0OVMh|ryP MWXTRW5ITVJ?
Mo-T MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfmTWM2OD1|Mj61NFQ3KM7:TR?= NF;4c5hUSU6JRWK=
SW1088 M{LaT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTN{Lkm4NFEh|ryP Ml;zV2FPT0WU
LB2518-MEL NF73PWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\xTWM2OD1|Mz6wO|k4KM7:TR?= MkX6V2FPT0WU
NCI-H82 M1HOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnzVopKSzVyPUOzMlE3PjFizszN MVLTRW5ITVJ?
LAMA-84 NIHucYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTN2Lk[wO|Mh|ryP MYTTRW5ITVJ?
KYSE-450 MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnzUHFKSzVyPUO0MlY4PzZizszN NYfYfFh6W0GQR1XS
LU-99A NXP2e4hST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTN3LkCwNFch|ryP Mny1V2FPT0WU
BE-13 MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Kzd2lEPTB;M{WuOlU1PSEQvF2= MVfTRW5ITVJ?
GAK MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTN3Lk[5OUDPxE1? M2Pkc3NCVkeHUh?=
NCI-H1573 MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknGTWM2OD1|NT64PFE5KM7:TR?= NH3jUoNUSU6JRWK=
AsPC-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTN4LkG1Nlch|ryP MUnTRW5ITVJ?
HDLM-2 Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnjeY86UUN3ME2zOk4{OTZizszN M3rUUnNCVkeHUh?=
NCI-H441 MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\4TWM2OD1|Nz6wOlkyKM7:TR?= M{PUVXNCVkeHUh?=
CAL-27 MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHaWYpKSzVyPUO3MlczOzFizszN NFPZOpZUSU6JRWK=
OVCAR-3 NEP5PWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjZdndKSzVyPUO5MlMyQDFizszN MnXPV2FPT0WU
RPMI-8226 M3u5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTN7LkW5PEDPxE1? NUjQeFVZW0GQR1XS
EFO-21 M4PYb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X2O2lEPTB;NECuOVgyPCEQvF2= NIPiO|FUSU6JRWK=
SNU-C2B NXzsUogzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfPeJFKSzVyPUSxMlUxQDRizszN MX\TRW5ITVJ?
VM-CUB-1 NGTDXYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3GzcmlEPTB;NEOuPFA{PyEQvF2= Ml3RV2FPT0WU
NCI-H2087 MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPVTWM2OD12NT6wNlM{KM7:TR?= NWjGS251W0GQR1XS
EW-16 M172NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfFZ2hKSzVyPUS2MlMyOzdizszN M4f2ZnNCVkeHUh?=
SK-N-AS NX;0ZnkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDuPZRrUUN3ME20Ok44OTZ5IN88US=> Mo\SV2FPT0WU
COR-L105 NF7RWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTR4Lki4OVch|ryP Mmi2V2FPT0WU
DEL Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn6xTWM2OD12OD6wOFI6KM7:TR?= M{HVWHNCVkeHUh?=
JVM-2 M2nm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTR6LkC1OVgh|ryP MkjvV2FPT0WU
KARPAS-45 M4H2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID0[FNKSzVyPUS5MlQ2OzhizszN MWPTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
+ Expand

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
+ Expand
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+55% PEG 300+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID